COVID-19 vaccine weekly safety report - 03-03-2022
Four COVID-19 vaccines are currently in use in Australia - Comirnaty (Pfizer), Spikevax (Moderna), Vaxzevria (AstraZeneca), and the recently approved Nuvaxovid (Novavax). To be registered for use, these vaccines must have met the TGA's high standards for quality, safety and effectiveness.
The TGA closely monitors reports of suspected side effects (also known as adverse events) to the COVID-19 vaccines. This is the most intensive safety monitoring ever conducted of any vaccines in Australia.
We encourage people to report suspected side effects, even if there's only a very small chance a vaccine was the cause. This provides valuable data that helps us identify potential safety issues. Often, however, these events are not caused by the vaccines. Learn more about causality and our COVID-19 vaccine safety monitoring and reporting activities.
A year of COVID-19 vaccine safety monitoring
This is the 52nd issue of the COVID-19 vaccine safety report. In the last year, 54 million vaccine doses have been given and we have received just over 112,000 suspected adverse event reports. We thank both health professionals and the general public for taking the time to report to us when they suspect an adverse reaction following vaccination. This has helped the TGA to monitor the safety of the vaccines and take action when needed.
Like other medicine regulators overseas, our surveillance system allows us to identify reporting patterns or trends that need to be investigated further. Safety concerns identified through these analyses and investigations are then communicated to the general public in this weekly report.
Public interest in the COVID-19 vaccines has been high, with over 4.5 million visits to the safety report over the past year. Being able to provide credible and up-to-date information about the benefits and risks associated with the vaccines has been our top priority. We have provided information about what we do know and where there are uncertainties, and responded quickly to dispel misinformation about the safety of the vaccines.
Summary
- Vaccination against COVID-19 is the most effective way to reduce deaths and severe illness from infection. The protective benefits of vaccination continue to far outweigh the potential risks.
- Like all medicines, COVID-19 vaccines may cause some side effects. The most frequently reported include injection-site reactions (such as a sore arm) and more general symptoms, like headache, muscle pain, fever and chills. This reflects what was seen in the clinical trials.
- We are carefully monitoring and reviewing reports of:
- myocarditis and pericarditis following mRNA vaccines, particularly in younger age groups
- thrombosis with thrombocytopenia syndrome (TTS), Guillain-Barre syndrome (GBS) and immune thrombocytopenia (ITP) following Vaxzevria (AstraZeneca).
- Myocarditis is a known but very rare side effect of Comirnaty (Pfizer) and Spikevax (Moderna). It is usually temporary, with most people getting better within a few days. Myocarditis is reported in 1-2 in every 100,000 people who receive Comirnaty (Pfizer) and Spikevax (Moderna). However, it is more common after the second dose in 12-17 year-old boys (11 cases per 100,000 Comirnaty doses and 16 cases per 100,000 Spikevax doses) and men under 30 (7 cases per 100,000 Comirnaty doses and 14 cases per 100,000 Spikevax doses).
- To 27 February 2022, the TGA has received 455 reports which have been assessed as likely to be myocarditis from about 36.5 million doses of Comirnaty (Pfizer) and 60 reports which have been assessed as likely to be myocarditis from about 3.7 million doses of Spikevax (Moderna).
- Thrombosis with thrombocytopenia syndrome (or TTS) is a very rare but serious side effect of Vaxzevria (AstraZeneca). Our analysis shows it is reported in about 2 in every 100,000 vaccinated people following the first dose. The risk of TTS is much lower after the second dose (0.3 in every 100,000 vaccinated people).
- No new cases of vaccine-related TTS have been reported this year.
To 27 February 2022, the total number of adverse event reports received where the brand of the COVID-19 vaccine was not specified was 511.
Reported side effects for COVID-19 vaccines
Anyone can report a suspected side effect, either:
- directly to the TGA
- through a health professional
- by calling the NPS MedicineWise Adverse Medicine Events phone line for consumers.
You can report anonymously.
Learn more about how to report a suspected side effect to a COVID-19 vaccine.
The most frequently reported side effects suspected to be associated with the vaccines include injection-site reactions, such as a sore arm, headache, muscle and joint pain, fever and chills. Skin reactions at the site of the injection are also common and can include pain, swelling, redness and an itchy rash. These are recognised side effects of vaccination and are usually transient and mild. More information about what to expect and how to manage any symptoms after you receive your vaccine are available from NPS MedicineWise - external site.
Vaccine safety in children and adolescents
The TGA is closely monitoring adverse event reports in people aged under 18 years. To 27 February 2022, we have received about 3,700 reports from approximately 3.5 million doses of Comirnaty (Pfizer) and Spikevax (Moderna) in 12-17 year olds. The most commonly reported reactions are chest pain, headache, dizziness, nausea and fever.
The TGA is also closely monitoring adverse event reports in 5-11 year olds. To 27 February 2022, we have received 774 reports from approximately 1.2 million Comirnaty (Pfizer) doses administered in this age group. The most common reactions reported included chest pain, vomiting, fever, headache, and nausea. We have received 14 reports of suspected myocarditis and/or pericarditis in this age group. Following review of information in the reports, none were likely to represent myocarditis. Two reports in 10-year-old boys possibly represented mild pericarditis when assessed against internationally accepted criteria for this condition.
Evidence from clinical trials and real-world experience from overseas indicate that side effects most commonly seen in this age group were mild and temporary similar to the safety profile in older populations. In clinical trials - external site of over 2000 children, most side effects were reported in the first 2-3 days after vaccination with the most common being a sore arm (70% of children), headache (25%) and tiredness (25%).
In the US, over 8 million doses of the vaccine have already been given to children aged 5–11 from 3 November to 19 December 2021. A review of active and passive vaccine surveillance data - external site published by the US Centers for Disease Control and Prevention (CDC) found similar safety findings to the clinical trial with most side effects being mild. A survey conducted shortly after vaccination found that about 5% of children missed school (usually only a single day or less) after a first dose and 7% missed school after a second dose.
Reports of more serious effects following vaccination in children in the US were extremely rare with 100 reports from 8.7 million vaccine doses - the most common were fever, vomiting and in some cases seizures. Importantly, reports of myocarditis were also very rare in the US, with 11 confirmed reports from over 8 million doses - these were all mild cases.
New safety data from the AusVaxSafety survey indicates that the Comirnaty (Pfizer) vaccine is well tolerated in children aged 5-11 years - external site, with fewer adverse reactions reported after vaccination than in older Australians. The most frequently reported side effects include local reactions at the injection site such as pain, swelling, redness and itching. Headache and fatigue were also common.
More information and frequently asked questions about COVID-19 vaccines in children are available on the National Centre for Immunisation Research and Surveillance - external site website
Booster doses
The TGA is monitoring the safety of booster vaccine doses in adults. It is not expected that the types of side effects will be different to first and second vaccine doses based on the results of clinical trials - external site, and observations from regulators overseas - external site where more booster doses have been given. Together with other international regulators we are monitoring the type and frequency of adverse events after different vaccine combinations.
To 27 February 2022, approximately 11.4 million boosters or third doses have been administered in Australia. We have received approximately 4,100 reports of suspected adverse events identified as a third or booster dose. These reports do not suggest any emerging safety concerns with use of a booster dose as the pattern of adverse events is similar to those for first and second vaccine doses.
Our booster or third dose reports include a small number of cases of myocarditis and pericarditis (inflammation of the heart). This is a recognised risk with the Comirnaty (Pfizer) and Spikevax (Moderna) vaccines and we are closely monitoring these events. So far, reports after booster doses are very rare with myocarditis reported in less than 1 in every 100,000 people after they receive a booster dose. A US study of active and passive surveillance data - external site of COVID-19 vaccine booster doses (September 2021-February 2022) found a similar trend. In men aged 18-24 years, the reporting rate of likely myocarditis was less than 1 in 100,000 mRNA vaccine booster doses compared to about 6 in 100,000 second doses. There is no indication that these events are more serious than after earlier doses.
The most common adverse events reported to the TGA following a booster dose are swollen lymph nodes (also called lymphadenopathy), headache, fatigue, muscle pain and fever. Swollen lymph nodes are a normal and known side effect of vaccines and occur when the immune system is stimulated and were seen in the clinical trials. More detail about this potential side effect is given in a previous vaccine safety report on 6 January 2022.
What we know about the safety of different vaccine combinations
Based on data from the Australian Immunisation Register - external site, we can see that most people under the age of 50 years received 3 mRNA vaccines - this was most commonly 3 doses of Comirnaty (Pfizer). For people in the 50-59 age group, there was more of a mixed picture with over half of them receiving 3 doses of an mRNA vaccine and the rest getting an mRNA vaccine booster after receiving initial doses of Vaxzevria (AstraZeneca). In the over 60 age group, most people received an mRNA vaccine booster after getting Vaxzevria (AstraZeneca) for their first 2 doses.
For the adverse event reports received by the TGA following a booster dose, many do not give details about which COVID-19 vaccines the person received for their first and second doses. Taking into account the limitations in this reporting data, we have not observed any patterns of adverse events which suggests different vaccine combinations are more likely to lead to serious adverse events.
The US surveillance study of booster doses - external site found that in people who had received 3 mRNA doses, adverse reactions were reported less frequently after the booster dose than after the second dose.
To improve our vaccine safety monitoring, we encourage people reporting adverse events to tell us as much information as possible about their experience, including the type of COVID vaccines they have received, and which dose the adverse event relates to.
More information about how to report a suspected side effect to a COVID-19 vaccine is available on the TGA website.
Reports of death in people who have been vaccinated
Large scale vaccination means that some people will experience a new illness or die within a few days or weeks of vaccination. These events are often coincidental, rather than being caused by the vaccine. As the number of people being vaccinated has increased, so has reporting of fatal events with a temporal association with vaccination. Review of these individual reports and patterns of reporting does not suggest that the vaccines played a role in the vast majority of these deaths.
The TGA closely reviews all adverse events after COVID-19 vaccination where a fatal outcome is reported. Read more about this process in a previous report. Since the beginning of the vaccine rollout to 27 February 2022, about 54 million doses of COVID-19 vaccines have been given. The TGA has identified 11 reports where the cause of death was linked to vaccination from 772 reports received and reviewed. The deaths linked to vaccination occurred after the first dose of Vaxzevria (AstraZeneca) - 8 were thrombosis with thrombocytopenia syndrome (TTS) cases, 2 were linked to Guillain-Barre syndrome (GBS) and one was a case of immune thrombocytopenia (ITP).
The 11 deaths likely to be related to vaccination occurred in people aged 34-81 years old. There have been no deaths in children, adolescents or young adults determined to be linked to COVID-19 vaccination.
AusVaxSafety - a national survey on COVID-19 vaccine safety
AusVaxSafety actively collects responses from Australians about adverse events after they have received a COVID-19 vaccine. It tells us what proportion of people experience an adverse event and what the most common reactions are. It also measures how frequently people go to the doctor or miss work or study because of an adverse event. Reassuringly, survey results largely reflect what was seen in the clinical trials, with injection-site reactions, fatigue, headache, and muscle and joint pain being the most common reactions.
Results are given for everyone who has taken the survey, which is about 5 million Australians so far. Data is presented for each vaccine and for the first, second and third or booster doses. Vaccine safety data is also given for subgroups of the population including:
- children aged 5-11 age years) - external site
- adolescents - external site
- Aboriginal and Torres Strait Islander people - external site
- people affected by cancer or who have received a transplant - external site
- pregnant women - external site
For more details and results of the survey, go to the AusVaxSafety website - external site.
Comirnaty (Pfizer) mRNA vaccine
To 27 February 2022, about 36.5 million doses of Comirnaty (Pfizer) have been administered in Australia.
The TGA is actively investigating reports of myocarditis (inflammation of the heart) and/or pericarditis (inflammation of the membrane around the heart) associated with mRNA vaccines. We continue to work with international regulators on this safety signal (see below - external site).
Up-to-date information for Comirnaty (Pfizer), including details of potential side effects , can be found in the Consumer Medicine Information - external site (for consumers) and Product Information - external site (for health professionals).
Spikevax (Moderna) mRNA vaccine
The Spikevax (Moderna) vaccine can now be given to 6–11 year olds in Australia. This follows provisional approval by the TGA and a recommendation by the Australian Technical Advisory Group on Immunisation (ATAGI) - external site. There is not a separate paediatric formulation of the Spikevax (Moderna) vaccine. However, for the 6-11 year age group, the dose is half that used for the primary vaccine course in older children and adults. The Comirnaty (Pfizer) children's formulation continues to be the only COVID-19 vaccine approved for children who are 5 years of age. No COVID-19 vaccines are currently approved for children 4 years of age and under.
The TGA is closely monitoring the safety of this vaccine in children and adults. To 27 February 2022, about 3.7 million doses of Spikevax (Moderna) have been administered in Australia.
The TGA is actively investigating reports of myocarditis (inflammation of the heart) and/or pericarditis (inflammation of the membrane around the heart) associated with mRNA vaccines. We continue to work with international regulators on this safety signal (see below).
Up-to-date information for Spikevax (Moderna), including details of potential side effects, can be found in the Consumer Medicine Information - external site (for consumers) and Product Information - external site (for health professionals).
Nuvaxovid (Novavax) vaccine
The Nuvaxovid (Novavax) vaccine has been provisionally approved for adults in Australia after meeting the TGA's high standards for quality, safety and effectiveness. The use of the vaccine has just started and we have only received 32 reports of suspected adverse events. We are closely monitoring the safety of this vaccine and will provide more detail as the rollout progresses.
Adverse event reports for Nuvaxovid (Novavax) will begin to appear in the TGA's publicly accessible Database of Adverse Event Notifications in the next few weeks. Please be aware they are entered into the database without being assessed to determine if they were caused by the vaccines. Publication of an adverse event report in the DAEN does not mean that the details of the event have been confirmed, or that the event has been determined to be related to the vaccine.
Before being registered for use in Australia, the safety of Nuvaxovid (Novavax) was assessed in several placebo-controlled clinical trials which included about 34,000 participants. In one of the trials - external site, local reactions at the injection site, such as tenderness and pain, were reported by the majority of people but were more common after the second dose (79% of participants) than the first dose (58% of participants). More generalised symptoms, such as headache, muscle pain, fatigue and malaise, were also more commonly reported after the second dose (70% of participants) than the first (50%). These symptoms are recognised side effects of vaccination and are common with the other COVID-19 vaccines.
Serious adverse events were rare in the trials. Two cases of myocarditis were reported in young males after they received a second dose of the vaccine. However, a link to the vaccine could not be confirmed for these cases.
More information for Nuvaxovid (Novavax), including details about its ingredients and potential side effects, can be found in the Consumer Medicine Information - external site (for consumers) and Product Information - external site (for health professionals).
Vaxzevria (AstraZeneca) vaccine
To 27 February 2022, about 13.8 million doses of Vaxzevria (AstraZeneca) have been administered in Australia. However, very few doses are now being used, particularly since the end of 2021. This vaccine has recently received provisional approval to be used as a booster dose. Individuals seeking a booster dose of Vaxzevria (AstraZeneca) should discuss this with their health professional.
The TGA is closely monitoring rare reports of blood clots with low blood platelets (also called thrombosis with thrombocytopenia syndrome or TTS) linked to this vaccine, immune thrombocytopenia (ITP) and Guillain-Barre Syndrome (GBS). These are rare but serious side effects, with TTS reported in about 2 in every 100,000 people after receiving Vaxzevria (AstraZeneca) and ITP and GBS reported in about one in every 100,000 people. Detailed information of our analysis of these adverse effects is available in a previous vaccine safety report.
With only limited use of the Vaxzevria (AstraZeneca) vaccine now in Australia, we have not received any new reports of confirmed or probable TTS this year. The total number of TTS cases reported in Australia is 172. Of these, 148 (83 confirmed, 65 probable) were related to a first dose of Vaxzevria (AstraZeneca) and 24 to a second dose (5 confirmed, 19 probable).
More general information for Vaxzevria (AstraZeneca), including details of potential side effects can be found in the Consumer Medicine Information - external site (for consumers) and Product Information - external site (for health professionals).
Myocarditis and pericarditis with mRNA vaccines
ATAGI continues to emphasise that the protective benefits of the mRNA vaccines far outweigh the rare risk of these side effects in all eligible age groups - external site.
ATAGI advises that people who develop myocarditis attributed to their first vaccine dose should defer further doses of an mRNA COVID-19 vaccine and discuss this with their treating doctor.
For those with suspected pericarditis after a first dose, future dose recommendations depend on test results and the person's age and sex. Refer to expert Guidance on myocarditis and pericarditis after mRNA COVID-19 vaccines - external site for more information.
What are myocarditis and pericarditis?
Myocarditis is inflammation of the heart, and pericarditis is inflammation of the membrane around the heart. They can occur as rare adverse events after vaccination with the mRNA vaccines Comirnaty (Pfizer) and Spikevax (Moderna).
When do myocarditis and pericarditis occur?
Cases typically occur within 10 days, with symptom onset often within 5 days of vaccination. Some published evidence - external site found pericarditis symptoms may occur later, commonly 2-3 weeks after vaccination. Our analysis indicates that most of the patients with likely myocarditis experienced symptoms within 3 days of vaccination.
Do myocarditis and pericarditis occur after a booster dose?
Myocarditis and pericarditis can occur after a booster dose but this is rare. The rate of reporting of myocarditis and pericarditis is less than 1 in every 100,000 people after a booster dose. There is no indication that these events are more serious than after earlier doses.
To 27 February 2022, from approximately 11.4 million booster or third doses, we have received 9 reports of likely myocarditis and 38 reports of likely pericarditis for Comirnaty (Pfizer) and 8 reports of likely myocarditis and 11 reports of likely pericarditis for Spikevax (Moderna). The median age of affected individuals was 33 years old.
Myocarditis following COVID-19 vaccination is most likely to be reported in adolescents and young men, whereas the median age of people who have received a third or booster dose of a COVID-19 vaccine to date is 54 years. The TGA will continue to closely monitor myocarditis and pericarditis following booster or third doses as the booster roll-out extends to younger age groups.
We are also closely monitoring myocarditis and pericarditis with different vaccine combinations for first and second doses and boosters. At this point, although we have only a small number of reports of pericarditis and/or myocarditis, we have not seen any patterns or trends in the data to indicate any difference with mixed vaccine combinations.
Who is at risk of these heart problems?
Myocarditis is more commonly reported after the second dose in 12-17 year-old boys (11 cases per 100,000 Comirnaty doses and 16 cases per 100,000 Spikevax doses) and men under 30 (7 cases per 100,000 Comirnaty doses and 14 cases per 100,000 Spikevax doses). However, even in this population it remains rare.
A European review of myocarditis and pericarditis data in teenage boys and young men (12-29 years old) - external site found for Comirnaty, there were 2-6 extra cases of myocarditis per 100,000 vaccinated individuals after a second dose compared to unvaccinated individuals. For Spikevax, there were 13-19 extra cases of myocarditis per 100,000 vaccinated individuals compared to unvaccinated individuals. A study by the Centers for Disease Control and Prevention (CDC) (pdf,606kb) - external site in the US found in 18-39 years olds there was approximately 2 extra cases of myocarditis and pericarditis reported per 100,000 Comirnaty (Pfizer) second doses and 3 extra cases per 100,000 Spikevax (Moderna) second doses.
In Australia the rates of pericarditis are similar between the mRNA vaccines. Emerging Australian and international data indicate that pericarditis is more common in people under 50 years of age than in older people.
How serious are myocarditis and pericarditis?
Myocarditis is often mild, and cases usually resolve after a few days with treatment and rest. Some cases are more serious and need to be treated in hospital. Our analysis has found about half of the patients with suspected myocarditis were admitted to hospital. Nine people with likely myocarditis or pericarditis were treated in intensive care. This represents less than 1% of all likely cases. Most patients admitted to hospital were discharged within 4 days.
Evidence from a US surveillance survey (pdf,1.1Mb) - external site of patients who had myocarditis following vaccination indicates that most patients fully recover without lasting impacts on their quality of life or ability to work. The survey, which was conducted 3 months after the initial myocarditis diagnosis, involved mostly men under 30 years after their second vaccine dose (and their treating doctors). There were no deaths from myocarditis reported in these patients.
What myocarditis and pericarditis symptoms should I look out for?
We encourage people to seek medical attention if they experience symptoms that could suggest myocarditis or pericarditis. This includes chest pain, palpitations (irregular heartbeat), fainting or shortness of breath, particularly if they occur within 1-5 days of vaccination.
Initial tests for those presenting with symptoms include ECG, troponin levels and chest X-ray. Brief guidance on the initial assessment of children and adolescents with symptoms has been published by the Paediatric Research in Emergency Departments International Collaborative (PREDICT) network - external site.
What does the TGA know about Australian myocarditis and pericarditis cases?
Reports received by the TGA of suspected myocarditis and pericarditis for the 2 mRNA vaccines are provided in Table 1. We have reviewed these reports against an internationally accepted criteria to classify the likelihood of myocarditis. This assessment does not determine whether cases have been caused by vaccination. Tables 2 and 3 present the rates of myocarditis and pericarditis.
We have received a small number of reports of myocarditis and pericarditis after a third or booster dose. These reports are very rare and there is no indication that they are more serious than after earlier doses.
Comirnaty (Pfizer) (36.5 million doses given) | Spikevax (Moderna) (3.7 million doses given) | ||||
|---|---|---|---|---|---|
| All cases | Cases in adolescents (12-17 years) | All cases | Cases in adolescents (12-17 years) | ||
| Suspected myocarditis cases* | 1,106 | 187 | 144 | 27 | |
| Likely myocarditis†‡ | Level 1 | 37 | 7 | 1 | 0 |
| Level 2 | 337 | 104 | 47 | 15 | |
| Level 3 | 81 | 12 | 12 | 3 | |
| Unlikely myocarditis | 267 | 21 | 35 | 3 | |
| Insufficient information | 384 | 43 | 49 | 6 | |
| Suspected pericarditis cases | 2,391 | 158 | 236 | 12 | |
| Likely pericarditis£ | 849 | 63 | 74 | 3 | |
* Cases reporting both myocarditis and pericarditis are included in suspected myocarditis cases.
‡ Cases classified as level 1 are confirmed to be myocarditis based on strong clinical evidence including the patient's symptoms, and results of tests and imaging indicating a diagnosis of myocarditis. Level 2 cases are probably myocarditis based on a combination of symptoms and routine tests for heart conditions. Level 3 cases are possibly myocarditis based on symptoms and a doctor's report that myocarditis is the most likely diagnosis in the absence of medical tests and investigations. For all cases of suspected myocarditis, where possible, other known causes of the patient's symptoms or test results are ruled out before cases are classified.
† The youngest case classified as 'likely myocarditis' to date was 12 years old.
£ Classification of likely pericarditis is based on the patient's symptoms and test results and the absence of other known causes of pericarditis.
Rates of myocarditis by age, sex and dose are given for Comirnaty (Pfizer) and Spikevax (Moderna) in Table 2. The estimated reporting rates in Australia appear similar to overseas rates. The rates for Spikevax (Moderna) are less certain due to low numbers of cases overall. Rates of pericarditis by age are given for Comirnaty (Pfizer) and Spikevax (Moderna) in Table 3.
| Age (years) | All doses | Second doses | ||
|---|---|---|---|---|
| Rate* per 100,000 doses | Rate* per 100,000 doses | |||
| Male | Female | Male | Female | |
| 12-17 | 6.5 | 1.4 | 10.7 | 2.4 |
| 18-29 | 3.8 | 1.1 | 6.7 | 2.0 |
| 30-39 | 1.5 | 0.6 | 1.9 | 0.6 |
| 40-49 | 0.7 | 0.6 | 1.2 | 0.9 |
| 50-59 | 0.4 | 0.3 | 0.1 | 0.4 |
| 60-69 | 0.1 | 0.2 | 0 | 0 |
| 70+ | 0 | 0.1 | 0 | 0.4 |
| All ages* | 1.9 | 0.6 | 3.7 | 1.2 |
| Age (years) | All doses | Second doses | ||
|---|---|---|---|---|
| Rate* per 100,000 doses | Rate* per 100,000 doses | |||
| Male | Female | Male | Female | |
| 12-17 | 8.7 | 1.8 | 15.9 | 2.6 |
| 18-29 | 7.2 | 0.9 | 14.2 | 1.2 |
| 30-39 | 2.7 | 0.3 | 5.2 | 0 |
| 40-49 | 0.7 | 0.4 | 0 | 0 |
| 50-59 | 0.3 | 1.0 | 0 | 2.6 |
| 60-69 | 0 | 0 | 0 | 0 |
| 70+ | 0 | 0 | 0 | 0 |
| All ages* | 2.7 | 0.6 | 7.5 | 1.1 |
* The rate includes cases of myocarditis that occurred after vaccination but may not be vaccine related.
‡ To 27 February 2022, from about 1.2 million vaccine doses given, no likely cases of myocarditis have been reported in children aged 5-11 years.
| Age (years) | Rate* per 100,000 doses | |
|---|---|---|
| Comirnaty (Pfizer) | Spikevax (Moderna) | |
| 12-17 | 2.0 | 0.9 |
| 18-29 | 3.3 | 4.2 |
| 30-39 | 3.8 | 4.2 |
| 40-49 | 2.3 | 1.8 |
| 50-59 | 1.2 | 0.5 |
| 60-69 | 0.6 | 0.2 |
| 70+ | 0.2 | 0.0 |
| All ages* | 2.3 | 2.0 |
* The rate includes cases of pericarditis that occurred after vaccination but may not be vaccine related.
‡ To 27 February 2022, from about 1.2 million vaccine doses given, two possible cases of mild pericarditis have been reported in children aged 5-11 years. As this number is so low, we are unable to estimate reliable rates of pericarditis in this age group.
We continue to monitor Australian reports on myocarditis and pericarditis and will provide regular updates in this report as more information becomes available. We are also working closely with international medicines regulators to share emerging safety information.
For more information, see guidance on myocarditis and pericarditis - external site developed by ATAGI and the Cardiac Society of Australia and New Zealand (CSANZ).
Useful links
Tested positive for COVID-19? Find out what you need to do - external site
ATAGI update following weekly COVID-19 meeting - 23 February 2022 - external site
The latest vaccine recommendations from ATAGI - external site
COVID-19 vaccines: Frequently asked questions - 23 February 2022 - external site
COVID vaccines - is it true? - 17 February 2022 - external site
RMIT ABC Fact Check - external site
Coronavirus (COVID-19) case numbers and statistics - external site
Australia's COVID-19 vaccine rollout - external site
Australian Government Department of Health COVID-19 vaccines hub - external site
COVID vaccine information in your language - external site
Database of Adverse Event Notifications (DAEN)
Nuvaxovid (Novavax) vaccine – clinical trials
Comirnaty (Pfizer) vaccine - phase III clinical trial - external site
Comirnaty (Pfizer) vaccine - clinical trials in children under 12 years - external site
Vaxzevria (AstraZeneca) vaccine - phase III clinical trial - external site
Spikevax (Moderna) vaccine - phase III clinical trial - external site
-
COVID-19 vaccine weekly safety report - 10-03-2022
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines. -
COVID-19 vaccine weekly safety report - 24-02-2022
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines. -
COVID-19 vaccine weekly safety report - 14-04-2022
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.